T-cell Therapy

T-cell Therapy Market Outlook

The global T-cell therapy market is projected to reach approximately USD 24 billion by 2035, growing at a compound annual growth rate (CAGR) of around 20% from 2025 to 2035. This robust growth is primarily driven by the increasing prevalence of cancer and chronic diseases, rising investments in immunotherapy research, and an expanding pipeline of innovative therapies. Furthermore, advancements in genetic modification techniques and the development of personalized medicine are facilitating the creation of more effective T-cell therapies. The growing awareness about the benefits of T-cell therapies in treating various life-threatening conditions, combined with supportive government initiatives and funding for clinical trials, is also expected to bolster market growth significantly.

Growth Factor of the Market

One of the chief growth factors of the T-cell therapy market is the rising incidence of various forms of cancer, which has propelled the demand for innovative treatment modalities like T-cell therapies. These therapies have shown remarkable efficacy in treating hematological malignancies, showcasing the potential for improved patient outcomes. Moreover, advancements in cell manufacturing technologies and the streamlined regulatory pathways have catalyzed the development and approval processes for T-cell therapies, thereby enhancing their availability. The increasing funding for research in immunotherapies, particularly in CAR-T and TCR-T cell therapies, is pivotal in driving innovation and expanding treatment options. Additionally, collaborations between biotechnology firms and academic institutions are further fostering advancements in T-cell therapy research and development, propelling the market forward.

Key Highlights of the Market

• Significant growth driven by the advancement of personalized medicine in cancer treatment.
• Increasing collaborations among biotech companies to enhance research efforts.
• Rising awareness regarding the efficacy of T-cell therapies.
• Expansion of production capabilities to meet the growing demand for T-cell therapies.
• Increasing prevalence of autoimmune and infectious diseases, boosting market potential.

By Product Type

CAR-T Cell Therapy:

CAR-T cell therapy has emerged as a revolutionary treatment in the T-cell therapy market, particularly for hematologic malignancies. This therapy involves modifying T-cells to express chimeric antigen receptors (CARs), allowing them to identify and attack cancer cells more effectively. Given its remarkable efficacy in treating conditions like acute lymphoblastic leukemia and certain types of non-Hodgkin lymphoma, CAR-T cell therapy has gained significant attention and investment. The increasing number of clinical trials and FDA approvals for CAR-T products is further fuelling its adoption. Additionally, research is underway to explore CAR-T therapy's potential applications beyond oncology, including autoimmune diseases, which could open new avenues for market growth.

TCR-T Cell Therapy:

TCR-T cell therapy focuses on engineering T-cells to express T-cell receptors (TCRs) that can recognize specific antigens presented by cancer cells. This innovative approach allows for targeting a broader range of tumors compared to CAR-T therapies, particularly those expressing minor histocompatibility antigens. As research in TCR-T cell therapy progresses, it shows promising results in clinical trials, demonstrating its potential to treat solid tumors. Additionally, the ability to target both hematological and solid tumors increases its attractiveness in the oncology domain, indicating a robust growth trajectory for this segment in the T-cell therapy market.

TIL Therapy:

Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cell transfer that utilizes T-cells that naturally migrate into tumors. This therapy capitalizes on the body’s own immune response to eliminate cancer cells. TIL therapy has shown great promise, particularly in melanoma and other solid tumors, showcasing significant remission rates. The increasing focus on harnessing the body’s immune system for cancer treatment has intensified research and development in TIL therapies. Moreover, the ongoing advancements in manufacturing and optimizing TIL therapies for broader applications are expected to enhance their market presence in the coming years.

T-cell Vaccines:

T-cell vaccines aim to enhance the immune system's ability to fight cancer by stimulating T-cell responses against specific tumors. This proactive approach to cancer therapy is gaining traction as it complements existing treatment modalities, potentially leading to better patient outcomes. While still in the experimental stages for many types of cancers, several clinical trials are underway, demonstrating promising results. As the understanding of tumor antigens improves, T-cell vaccines are likely to become integral in combination therapies, boosting their adoption in the market. The ability to personalize vaccines based on individual tumor profiles further enhances their potential in the T-cell therapy market.

T-cell Receptor Gene Therapy:

T-cell receptor gene therapy is an innovative field that focuses on genetically modifying T-cells to express specific T-cell receptors that target cancer cells. This therapy not only enhances the precision of the immune response but also improves the effectiveness of T-cells in recognizing and attacking tumors. The increasing research efforts and successful clinical trials in this area point towards a significant growth outlook, as it enables more personalized and effective treatment strategies. Moreover, the ability to target a wider range of cancers through engineered T-cell receptors offers a substantial opportunity for market expansion and diversification.

By Application

Oncology:

The oncology segment is the largest and most dynamic area within the T-cell therapy market, driven primarily by the urgent need for effective cancer treatments. T-cell therapies, particularly CAR-T and TCR-T therapies, have demonstrated significant success in treating various malignancies, leading to their rapid adoption in clinical practice. The increasing incidence of blood cancers and solid tumors has fueled market growth, with T-cell therapies offering hope for patients who have exhausted other treatment options. Furthermore, ongoing research into expanding the application of T-cell therapies to different cancer types continues to enhance the segment's growth potential significantly.

Autoimmune Diseases:

The application of T-cell therapies in autoimmune diseases represents a burgeoning segment, as traditional treatment methods often fail to provide lasting results. By specifically targeting and modifying T-cell responses, these therapies aim to re-establish immune tolerance and mitigate disease symptoms. Recent clinical trials have shown promise in using T-cell therapies for conditions such as multiple sclerosis and rheumatoid arthritis, which could significantly alter the treatment landscape. As research progresses and more understanding is gained about the mechanisms of autoimmune diseases, the application of T-cell therapies in this area is expected to expand, driving further growth in the market.

Infectious Diseases:

T-cell therapies are also gaining traction in the treatment of infectious diseases, especially as novel approaches to combat viruses and persistent infections. The capability of T-cells to specifically target infected cells makes them a viable option for conditions like HIV, hepatitis, and other viral infections. Research in this domain is actively exploring the potential of engineered T-cells to provide durable immune responses against these pathogens. As public health challenges related to infectious diseases continue to grow, the role of T-cell therapies in enhancing immune responses could lead to significant advancements and market growth in this application area.

Immunodeficiency Disorders:

Immunodeficiency disorders, including congenital immunodeficiencies and secondary immunodeficiencies, present an opportunity for T-cell therapies to enhance immune function. These therapies can restore T-cell populations and functionality, providing a critical intervention for affected individuals. The increasing recognition of T-cell therapies in improving outcomes for patients with immunodeficiency disorders is leading to ongoing research and clinical trials in this area. As outcomes from these efforts become more evident, the market for T-cell therapies targeting immunodeficiency disorders is expected to grow significantly, representing a key opportunity for stakeholders.

Others:

This category includes various niche applications of T-cell therapies that do not fall under the primary therapeutic areas. These may include chronic inflammatory diseases, transplant rejection, and other conditions where T-cell modulation could play a role. As research expands, new therapeutic applications for T-cell therapies are likely to be discovered, further driving market growth. The versatility of T-cells in targeting a wide range of diseases holds the potential for innovative treatment strategies, which will continue to emerge and evolve in this segment of the market.

By Distribution Channel

Hospitals:

Hospitals serve as a primary distribution channel for T-cell therapies, given their capacity to provide comprehensive oncology care. The presence of specialized oncology departments and access to advanced medical technologies enables hospitals to administer T-cell therapies effectively. Furthermore, the affiliation of hospitals with research institutions enhances their ability to participate in clinical trials, establishing a robust pipeline for T-cell therapies. As patient demand for innovative and personalized treatments grows, hospitals are expected to increasingly adopt T-cell therapies, solidifying their role as a key distribution channel in the market.

Clinics:

Clinics play a vital role in the distribution of T-cell therapies, particularly as outpatient settings for monitoring and follow-up care. Their accessibility and personalized approach make them a favorable option for patients requiring regular treatment and support. The growth of specialized oncology clinics that focus on immunotherapies is facilitating the wider adoption of T-cell therapies outside hospital settings. As awareness of T-cell therapies increases, clinics are likely to become an essential part of the treatment continuum, offering patients convenient access to groundbreaking therapies.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are increasingly becoming a viable distribution channel for T-cell therapies, particularly for those that can be administered in outpatient settings. Their ability to provide cost-effective and efficient care for patients undergoing T-cell therapies is driving their adoption. ASCs streamline the process of treatment by reducing wait times and enhancing patient convenience. As regulatory guidelines evolve and more T-cell therapies gain approval for outpatient use, the role of ASCs in the distribution of T-cell therapies is anticipated to grow significantly.

Research Institutes:

Research institutes are crucial for the distribution of T-cell therapies, particularly in the context of clinical trials and innovative research. These institutions often lead the charge in developing new therapies and advancing scientific understanding in the field of immunotherapy. As centers of excellence, research institutes attract collaborations and funding that facilitate the development of T-cell therapies. Their contributions to clinical trials often pave the way for therapies to reach the market, making them integral to the overall T-cell therapy ecosystem.

Others:

This category encompasses various other distribution channels, including specialty pharmacies and academic centers that may offer T-cell therapies. These channels are emerging as essential components in delivering innovative treatments to patients, particularly in regions where access to traditional healthcare facilities may be limited. The growth of telemedicine and digital health solutions is also influencing how T-cell therapies are distributed, providing more patient-centric options for treatment delivery. As the market evolves, these alternative distribution channels will continue to adapt and expand, contributing to the broader T-cell therapy landscape.

By Ingredient Type

CD19:

CD19 is a critical target antigen in the development of CAR-T cell therapies, particularly for treating B-cell malignancies such as acute lymphoblastic leukemia and certain types of non-Hodgkin lymphoma. The targeting of CD19 has shown impressive clinical results, leading to the approval of several CD19-targeting therapies. The ongoing research into optimizing CD19-targeting strategies aims to enhance efficacy and reduce potential adverse effects. As the understanding of CD19's role in B-cell biology progresses, further innovations in CD19-targeting therapies are expected, solidifying its importance in the T-cell therapy ingredient landscape.

CD22:

CD22 is another promising target for T-cell therapies, particularly in the context of B-cell malignancies. Targeting CD22 offers an alternative approach for patients who may not respond to CD19-targeting therapies. The dual targeting of CD19 and CD22 is also being explored to improve therapeutic outcomes, especially in relapsed or refractory cases. As research expands into the efficacy and safety of CD22-targeting tactics, this antigen is poised to play a significant role in developing next-generation T-cell therapies, enhancing the overall therapeutic arsenal against B-cell cancers.

BCMA:

BCMA (B-cell maturation antigen) has emerged as a critical target in the field of multiple myeloma treatment, representing a significant advancement in T-cell therapies. BCMA-targeting CAR-T therapies have demonstrated remarkable efficacy in treating relapsed or refractory multiple myeloma, leading to substantial clinical interest and investment. The potential for BCMA-targeting strategies to improve long-term outcomes for patients highlights the importance of this ingredient in the T-cell therapy market. Ongoing research and clinical trials exploring BCMA's role further solidify its significance as a target for innovative T-cell therapies.

GD2:

GD2 is a disialoganglioside that represents a promising target for T-cell therapies, particularly in the treatment of neuroblastoma and other tumors. Targeting GD2 has shown potential for eliciting robust immune responses, enabling T-cells to effectively attack tumor cells. The application of GD2-targeting therapies is gaining traction in pediatric oncology, where neuroblastoma remains a challenging condition. As research continues to explore GD2's role in various malignancies, this ingredient is expected to find its place in the evolving landscape of T-cell therapies.

NY-ESO-1:

NY-ESO-1 is a cancer/testis antigen that has garnered attention in T-cell therapy development due to its restricted expression in normal tissues and high prevalence in various cancers. NY-ESO-1-targeting T-cell therapies have shown promise in treating melanoma and other solid tumors, with ongoing research exploring their efficacy in combination with other treatment modalities. The unique profile of NY-ESO-1 as a target offers an opportunity to specifically enhance T-cell responses against a range of tumors, positioning it as a vital ingredient in the development of innovative T-cell therapies.

By Region

The North American region holds a dominant position in the T-cell therapy market, accounting for nearly 45% of the global market share in 2025. This is primarily due to the presence of advanced healthcare infrastructure, robust research and development activities, and a high prevalence of cancer-related disorders. The increasing number of FDA approvals for T-cell therapies has further propelled market growth in this region. Moreover, the collaborative efforts between biotech companies and academic institutions are expected to drive innovation and enhance the therapeutic landscape in North America. The CAGR for North America is projected to be approximately 21% during the forecast period, indicating strong growth potential.

Europe follows North America, contributing around 30% to the global T-cell therapy market in 2025. The region's growth is supported by increasing investments in immunotherapy research, favorable regulatory frameworks, and rising patient awareness regarding advanced cancer treatments. Countries such as Germany, France, and the UK are leading the way in T-cell therapy research, with numerous clinical trials underway. Additionally, the expansion of healthcare facilities and the growing emphasis on personalized medicine are expected to bolster market growth in Europe, maintaining a CAGR of around 19% during the forecast period.

Opportunities

The T-cell therapy market presents numerous opportunities for growth, primarily driven by the increasing focus on personalized medicine and the evolving landscape of cancer treatments. As more patients seek targeted therapies that offer improved efficacy and reduced side effects, the demand for innovative T-cell therapies is expected to rise significantly. Furthermore, the expansion of research initiatives and funding for clinical trials will foster the development of next-generation T-cell therapies that can target a broader range of diseases. The growing awareness among healthcare professionals and patients about the benefits of T-cell therapies will also contribute to market growth. Additionally, emerging markets in Asia-Pacific and Latin America are becoming increasingly attractive for T-cell therapy providers, offering untapped opportunities for expansion and collaboration.

Another significant opportunity lies in the potential to enhance existing T-cell therapies through combination approaches. Research exploring the synergistic effects of combining T-cell therapies with other treatment modalities, such as checkpoint inhibitors and targeted therapies, is gaining momentum. This integrative approach may lead to more effective treatment regimens and improved patient outcomes, further propelling the T-cell therapy market. Additionally, the implementation of advanced technologies, such as artificial intelligence and machine learning, in treatment design and patient stratification could enhance therapeutic precision, resulting in a more tailored approach to T-cell therapy. As the market continues to evolve, stakeholders must capitalize on these opportunities to drive innovation and growth.

Threats

Despite the promising outlook, the T-cell therapy market faces several threats that could impede growth. One of the primary challenges is the high cost associated with T-cell therapies, which can limit access for patients and healthcare systems. These therapies often require complex manufacturing processes and specialized infrastructure, leading to elevated treatment costs that may not be covered by insurance. As a result, affordability and accessibility issues could restrict the widespread adoption of T-cell therapies, particularly in lower-income regions. Additionally, the regulatory landscape surrounding T-cell therapies can be complex and time-consuming, potentially delaying the introduction of new products to the market.

Moreover, the emergence of competition from alternative treatment modalities, such as monoclonal antibodies and conventional therapies, presents a challenge for T-cell therapy providers. As numerous treatment options become available, the market may become crowded, leading to increased pressure on pricing and revenue generation. Furthermore, the risk of adverse effects and complications associated with T-cell therapies can deter patients and healthcare providers from pursuing these options. Ensuring the safety and efficacy of T-cell therapies through rigorous clinical trials and post-marketing surveillance will be essential to mitigate these threats and maintain patient trust in these innovative treatments.

Competitor Outlook

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation (now part of Bristol-Myers Squibb)
• Regeneron Pharmaceuticals, Inc.
• Amgen Inc.
• Merck & Co., Inc.
• Juno Therapeutics (a Celgene subsidiary)
• AstraZeneca PLC
• Adaptimmune Therapeutics PLC
• Ziopharm Oncology, Inc.
• Bluebird Bio, Inc.
• Caribou Biosciences, Inc.
• Allogene Therapeutics, Inc.
• Fate Therapeutics, Inc.

The competitive landscape of the T-cell therapy market is characterized by the presence of several established pharmaceutical and biotechnology companies actively engaged in research, development, and commercialization of innovative therapies. Major players are investing significantly in R&D to enhance the efficacy and safety of T-cell therapies while also expanding their product portfolios through collaborations and partnerships. The intense competition fosters innovation and drives advancements in T-cell therapy technologies, which in turn benefits patients with various malignancies and disorders. Companies are also increasingly focusing on personalized medicine approaches to cater to the unique needs of individual patients, further solidifying their competitive edge in the market.

Novartis AG, a pioneer in CAR-T cell therapy, has made significant strides in the market with its Kymriah product, which was the first CAR-T therapy to receive FDA approval. The company's commitment to ongoing research and development initiatives is evident through its extensive pipeline of therapies targeting various cancers. Gilead Sciences, Inc. has also reinforced its position in the market through its acquisition of Kite Pharma, expanding its CAR-T product offerings and enhancing its capabilities in cell therapy. Bristol-Myers Squibb, through its acquisition of Celgene, has strengthened its foothold in the T-cell therapy domain, particularly with innovative TCR-T therapies catering to solid tumors. These key players continue to shape the competitive landscape by focusing on technological advancements, strategic collaborations, and expanding their global reach.

Adaptimmune Therapeutics has emerged as a strong contender in the T-cell therapy market due to its focus on TCR-T cell therapies and personalized treatment approaches. The company's commitment to advancing its proprietary technology platform enables the development of therapies targeting specific antigens associated with various cancers. Similarly, Allogene Therapeutics is making waves in the industry with its innovative allogeneic CAR-T therapies, which aim to provide off-the-shelf treatment options for patients. This emerging trend could potentially transform the T-cell therapy market, making treatments more accessible and affordable. As the competitive landscape continues to evolve, companies must remain agile and responsive to market dynamics to capitalize on growth opportunities.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AstraZeneca PLC
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Merck & Co., Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Bluebird Bio, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Gilead Sciences, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Fate Therapeutics, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Ziopharm Oncology, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Caribou Biosciences, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Allogene Therapeutics, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Adaptimmune Therapeutics PLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Juno Therapeutics (a Celgene subsidiary)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Celgene Corporation (now part of Bristol-Myers Squibb)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 T-cell Therapy Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Autoimmune Diseases
    • 6.1.3 Infectious Diseases
    • 6.1.4 Immunodeficiency Disorders
    • 6.1.5 Others
  • 6.2 T-cell Therapy Market, By Ingredient Type
    • 6.2.1 CD19
    • 6.2.2 CD22
    • 6.2.3 BCMA
    • 6.2.4 GD2
    • 6.2.5 NY-ESO-1
  • 6.3 T-cell Therapy Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Clinics
    • 6.3.3 Ambulatory Surgical Centers
    • 6.3.4 Research Institutes
    • 6.3.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 T-cell Therapy Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global T-cell Therapy market is categorized based on

By Application

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Immunodeficiency Disorders
• Others

By Distribution Channel

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others

By Ingredient Type

• CD19
• CD22
• BCMA
• GD2
• NY-ESO-1

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation (now part of Bristol-Myers Squibb)
• Regeneron Pharmaceuticals, Inc.
• Amgen Inc.
• Merck & Co., Inc.
• Juno Therapeutics (a Celgene subsidiary)
• AstraZeneca PLC
• Adaptimmune Therapeutics PLC
• Ziopharm Oncology, Inc.
• Bluebird Bio, Inc.
• Caribou Biosciences, Inc.
• Allogene Therapeutics, Inc.
• Fate Therapeutics, Inc.